Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. When it gives the green light, H3K4me3 allows RNA polymerase II to move along DNA, transcribing it into RNA as it moves.

Gene Expression 52

Gene Expression Gene DNA RNA 52

Camargo

JULY 27, 2021

How and When to Incorporate PK Design into Your Gene Therapy Development Plan. It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy. PK Planning for Gene Therapy Development Programs.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Drug Discovery World

SEPTEMBER 27, 2023

HKG Epitherapeutics is a biotechnology company developing novel tools for the early detection of cancer and promoting healthy aging. Unlike genetics, where DNA sequences remain constant, epigenetic modifications are cell type-specific and can change over time due to a balance of enzymatic processes.

DNA 115

DNA Genetics Gene Medicine 115

Drug Discovery World

APRIL 17, 2024

DS: CAMP4 leverages research from co-founder Richard Young on how regulatory RNA (regRNA) molecules control the expression of genes. JMB: Regulatory RNAs (or regRNAS) are molecules that directly control the expression of nearby protein-coding genes. DS: You describe your therapeutics as RNA Amplifiers. How do they work?

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

pharmaphorum

JANUARY 26, 2023

In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA. Just one mutation can lead to a complete change in protein formation. Just one mutation can lead to a complete change in protein formation.

Genome 129

Genome Genomics Genome Project Genetics 129

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These systems include human and mouse cell lines, and even in vivo in live animals.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Roots Analysis

AUGUST 15, 2023

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52

Protein In-Vitro Production Reagent 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The failure of several late-stage trials highlights the challenging nature of HIV vaccine development. Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Drug Discovery World

AUGUST 16, 2023

Additionally, patients whose cancer has spread but who have not yet received chemotherapy, and whose primary tumours have markers of faults in genes linked to DNA repair pathways, tend to respond better to carboplatin. “Our findings paint a complex picture – with many, dynamic factors driving how tumours respond to treatment.”

Genetics 52

Genetics Gene Hormones RNA 52

The Pharma Data

JUNE 7, 2023

a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

pharmaphorum

OCTOBER 31, 2022

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing.

Genome 136

Genome Genomics Drugs RNA 136

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. HER2 is a protein that plays an important role in cancer cell growth and is found on the surface of cancer cells in a very high quantity in about 10-20% of breast cancers.

Development 52

Development DNA Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 21, 2024

Advances in this area are having a positive effect on both the commercial success of drug discovery and development organisations, as well as benefitting the health and wellbeing of the global population. Technology plays multiple roles in all stages of vaccine development,” says Kanekiyo. “It

Protein 52

Protein Vaccination Vaccine Development 52

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. link] pic.twitter.com/XHh0Y009fK.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Genetics 130

Genetics Gene Expression DNA Antibody 130

Roots Analysis

MARCH 8, 2023

INTRODUCTION TO EXOSOMES Exosomes are extracellular vesicles, which have endosomal origin and may contain different biomolecules, including proteins, DNA, lipids, miRNA or RNA , based on the type of cell of their origin and its conditions. The most essential component of exosome biogenesis is the formation of ESCRT.

RNA 52

RNA Drug Delivery DNA Development 52

XTalks

APRIL 6, 2022

The personalized ctDNA blood test uses the RaDaR™ assay, a liquid biopsy platform developed by the company Inivata. Cancerous cells and tumors release small fragments of DNA into the bloodstream called circulating tumour DNA (ctDNA). Photo source: Inivata. Around 85 percent of cases are non-small cell lung cancer (NSCLC).

DNA 105

DNA In-Vitro Doctors Doctor 105

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

APRIL 11, 2023

The molecule, known as lissodendoric acid A, appears to counteract other molecules that can damage DNA, RNA and proteins and even destroy whole cells. Dysregulation of mitophagy is closely linked to the development of several diseases, with USP30 modulation offering a potential treatment.

Research 52

Research Drugs Life Science RNA 52

Drug Discovery World

JANUARY 26, 2023

The molecule, known as lissodendoric acid A, appears to counteract other molecules that can damage DNA, RNA and proteins and even destroy whole cells.

RNA 52

RNA Medicine DNA Protein 52

pharmaphorum

AUGUST 5, 2021

Bayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will boost its ability to develop medicines against targets once considered “undruggable.” ” Bayer is paying $1.5

DNA 52

DNA Gene Therapy Protein Gene 52

Drug Discovery World

JANUARY 23, 2023

“Put simply, radioresistant GBM cells prefer to stock up on fatty acids instead of utilising them as an energy source in order to reduce mitochondrial reactive oxygen species that may cause damage to their DNA, RNA, and proteins, and, in turn, cell death,” explains Prof Youn.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

pharmaphorum

OCTOBER 12, 2021

It was the first drug to be approved in the US that works by RNA interference – blocking the strand of RNA that transcribes a defective gene in a patient’s DNA into a misfolded protein that leads to a disease. Vutrisiran is under regulatory review in Europe and the US, with decisions due in 2022.

RNA 52

RNA DNA Drugs Protein 52

XTalks

AUGUST 12, 2020

The identification of T cells that essentially ‘hide’ the virus has significant implications for developing therapeutic strategies to improve the treatment and long-term management of HIV. Transcriptionally active’ cells in which HIV RNA is actively transcribed to make copies of the virus (despite long-term ART).

RNA 52

RNA Protein DNA In-Vivo 52

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

Drug Discovery World

JANUARY 3, 2023

Matthew Clark , CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. cytokine-receptor disrupters).

DNA 52

DNA Protein Drugs RNA 52

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

The Pharma Data

OCTOBER 19, 2020

. “Innovation in cancer treatment is realized through collaboration, and the physicians and researchers at Emory’s Winship Cancer Institute have consistently shown their commitment to developing novel cancer therapies using this collaborative approach,” said Chadi Nabhan , M.D., Ramalingam , M.D.,

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. Its job is to carry coding information that is essential to the translation and processing of functional proteins.

RNA 52

RNA Protein Vaccination Vaccine 52

Drug Discovery World

MARCH 7, 2023

Powers taught for more than six years at the National Institutes of Health, on medical product development and commercialisation, and at Georgetown Law School as an adjunct professor. Dr Janette Thomas, CEO, Five Alarm Bio Five Alarm Bio is an anti-ageing therapeutics company, which completed a seed investment round in early 2023.

Life Science 98

Life Science DNA Clinical Development Development 98

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. In addition, Dr. Bahassi stressed that the simple enumeration of CTCs will not contribute significantly to the development of improved or more personalized cancer treatments.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

Delveinsight

DECEMBER 13, 2020

Due to hepatitis C, most people develop cirrhosis, or scarring of the liver, before liver cancer; about 5–25% of patients with chronic hepatitis C develop cirrhosis over 10–20 years. Research and development in Hepatitis. 2b) was developed to maintain a steady level of an active drug and reduce the frequency of administration.

Genotype 52

Genotype FDA Approval DNA Drugs 52